newsfilter
← Latest News
ACCESS Newswire·

Protagonist Therapeutics Reports Granting of Inducement Awards

PTGX
  • Protagonist Therapeutics granted inducement awards to three newly hired employees on July 15, 2026.
  • The awards totaled 12,600 stock options & 3,330 restricted stock units (RSUs) under the company's Amended & Restated Inducement Plan.
  • The option exercise price was set at $135.46, matching the Nasdaq closing price on the grant date.
  • Options vest over four years with 25% vesting on the first anniversary & the remainder in equal monthly installments thereafter.
  • RSUs vest one-fourth annually over a four-year period.
  • The compensation committee approved the awards as material inducements under Nasdaq Marketplace Rule 5635(c)(4).
  • ICOTYDE™ launched in the U.S. in March 2026 for plaque psoriasis & is in Phase 3 trials for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
  • Rusfertide is under FDA priority review for polycythemia vera following Phase 3 development.
  • The company maintains additional pipeline programs targeting IL-17, obesity, hepcidin, IL-4, & amylin.